Investment
Launched Serif Biomedicines with $50M in founding capital to develop modified DNA genetic medicines.
Serif Biomedicines
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Serif Biomedicines
AWS collaboration
Generate Biomedicines
Choosing Science
Choosing Science - 2026 Annual Letter
Expedition Medicines
Extuitive